Axel-Sven Malkomes
Director/Miembro de la Junta en CELLECTIS S.A. .
Fortuna: - $ al 30/04/2024
Cargos activos de Axel-Sven Malkomes
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CELLECTIS S.A. | Director/Miembro de la Junta | 28/06/2022 | - |
| Independent Dir/Board Member | 28/06/2022 | - | |
Medigene Immunotherapies GmbH
 Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Director Ejecutivo | - | - |
Historial de carrera de Axel-Sven Malkomes
Antiguos cargos conocidos de Axel-Sven Malkomes.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| MEDIGENE AG | Director Financiero/CFO | 01/04/2019 | 31/03/2022 |
| BARCLAYS PLC | Director/Miembro de la Junta | 01/03/2016 | 01/03/2019 |
| Corporate Officer/Principal | 01/03/2016 | 01/03/2019 | |
| SOCIÉTÉ GÉNÉRALE | Corporate Officer/Principal | 01/01/2010 | 01/01/2016 |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
 3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Inversor de Capital Privado | - | 01/01/2010 |
| MERCK KGAA | Corporate Officer/Principal | - | - |
Estadísticas
Internacional
| Alemania | 5 |
| Francia | 3 |
| Reino Unido | 2 |
Operativa
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Private Equity Investor | 1 |
Sectorial
| Health Technology | 5 |
| Finance | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| MEDIGENE AG | Health Technology |
| BARCLAYS PLC | Finance |
| SOCIÉTÉ GÉNÉRALE | Finance |
| MERCK KGAA | Health Technology |
| CELLECTIS S.A. | Health Technology |
| Empresas privadas | 2 |
|---|---|
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Finance |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
- Bolsa de valores
- Insiders
- Axel-Sven Malkomes
- Experiencia
